Close Menu

Beckman Coulter

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Cogenics' services will complement those already offered by Beckman Coulter's Agencourt Biosciences business.

Short Reads

Premium

Helicos, Agencourt, Illumina, RainDance Technologies, Ontario Institute for Cancer Research, VWR International, ZyGem, University of Queensland, University of Michigan, Genomatix

Beckman said the closing payment for the deal would fixed at $780 million. It also said that it would eliminate Olympus' immunoassay product line and related R&D efforts after the closing of the deal.

The $800 million acquisition will strengthen Beckman Coulter's presence in the clinical chemistry market. The firm does not anticipate a change in its current investment grade ratings due to the new debt.

IP Roundup

Premium

CalTech, Beckman Coulter, Genisphere, Seiko Epson

Recent Research Papers of Note

Premium

Included is a paper on the use of a mass spectrometry-based strategy for the absolute quantification of protein complex components, one using SISCAPA technology, and one showing that top-down proteomics can be done using CID on a q-TOF instrument.

News Scan

Premium

Trevena, Ligand Pharmaceuticals, Ibidi, Seahorse Bioscience

Regardless of the outcome of the first phase of the trial, Life Technologies declared victory last week, saying that the patents are irrelevant for current or future versions of the SOLiD technology.

Pages

The Associated Press reports that a state board in Texas has asked ANDE, a maker of rapid DNA machines, to halt its work there.

James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.

Researchers find that a 30-year-old skull comes from a narwhal-beluga hybrid, according to Science News.

In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.